Relief Therapeutics Holding Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 6/6

Relief Therapeutics Holding har ett totalt eget kapital på CHF36.7M och en total skuld på CHF0.0 vilket ger sin skuldsättningsgrad till 0%. Dess totala tillgångar och totala skulder är CHF53.2M respektive CHF16.6M.

Viktig information

Skuldsättning i förhållande till eget kapital

CHF 0

Skuld

Räntetäckningsgrad	n/a
Kontanter	CHF 15.08m
Eget kapital	CHF 36.66m
Summa skulder	CHF 16.56m
Totala tillgångar	CHF 53.22m

Nya uppdateringar om finansiell hälsa

We Think Relief Therapeutics Holding (VTX:RLF) Can Easily Afford To Drive Business Growth

Oct 09

Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?

May 05

Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?

Oct 04

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Apr 23

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Sep 25

Recent updates

We Think Relief Therapeutics Holding (VTX:RLF) Can Easily Afford To Drive Business Growth

Oct 09

Relief Therapeutics Holding SA's (VTX:RLF) Share Price Boosted 52% But Its Business Prospects Need A Lift Too

Sep 03

Relief Therapeutics Holding SA (VTX:RLF) Surges 52% Yet Its Low P/S Is No Reason For Excitement

Sep 03

Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?

May 05

Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?

Oct 04

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Apr 23

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Sep 25

Analys av finansiell ställning

Kortfristiga skulder: RLF s kortfristiga tillgångar ( CHF19.7M ) överstiger dess kortfristiga skulder ( CHF5.0M ).

Långfristiga skulder: RLF s kortfristiga tillgångar ( CHF19.7M ) överstiger dess långfristiga skulder ( CHF11.6M ).

Skuld till eget kapital Historik och analys

Skuldnivå: RLF är skuldfri.

Minska skulden: RLF har inga skulder jämfört med för 5 år sedan när dess skuldsättningsgrad var 12.2%.

Balansräkning

Analys av kontantbanan

För företag som i genomsnitt har gått med förlust tidigare bedömer vi om de har minst 1 års kassaflöde.

Stabil Cash Runway: Även om olönsamma RLF har tillräckligt med cash runway i mer än 3 år om den bibehåller sin nuvarande positiva fritt kassaflöde-nivå.

Prognos Cash Runway: RLF är olönsam men har tillräckligt med kassaflöde i mer än 3 år, även när det fria kassaflödet är positivt och krymper med 12 % per år.

Upptäck friska företag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/05/19 12:17
Aktiekurs vid dagens slut	2025/05/19 00:00
Intäkter	2024/12/31
Årlig intjäning	2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Relief Therapeutics Holding SA bevakas av 2 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Alexandre Müller	Research Dynamics
Bob Pooler	ValuationLAB AG

Relief Therapeutics Holding Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 6/6

Viktig information

Nya uppdateringar om finansiell hälsa

Relief Therapeutics Holding SA Auditor Raises 'Going Concern' Doubt

We Think Relief Therapeutics Holding (VTX:RLF) Can Easily Afford To Drive Business Growth

Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?

Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Recent updates

Relief Therapeutics Holding SA, Annual General Meeting, Jun 12, 2025

Relief Therapeutics Holding SA Auditor Raises 'Going Concern' Doubt

Relief Therapeutics Holding SA to Report First Half, 2025 Results on Aug 29, 2025

Renexxion, LLC cancelled the acquisition of Relief Therapeutics Holding SA (SWX:RLF) in a reverse merger transaction.

Relief Therapeutics Holding SA to Report Fiscal Year 2024 Results on Apr 10, 2025

New minor risk - Financial data availability

Relief Therapeutics Holding SA Announces Final Readout of PKU GOLIKE Clinical Trial

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Renexxion, LLC signed a letter of intent to acquire Relief Therapeutics Holding SA (SWX:RLF) in a reverse merger transaction valued at $260 million.

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents

We Think Relief Therapeutics Holding (VTX:RLF) Can Easily Afford To Drive Business Growth

Relief Therapeutics Holding SA Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Holding SA Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-Of-Concept Study; Topline Results Expected in October 2024

New minor risk - Shareholder dilution

Relief Therapeutics Holding SA's (VTX:RLF) Share Price Boosted 52% But Its Business Prospects Need A Lift Too

Relief Therapeutics Holding SA (VTX:RLF) Surges 52% Yet Its Low P/S Is No Reason For Excitement

Relief Therapeutics Holding SA Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

Relief Therapeutics Holding SA to Report First Half, 2024 Results on Aug 30, 2024

Relief Therapeutics Holding Announces Michelle Lock Will Not Stand for Re-Election as A Member of the Board of Directors

Relief Therapeutics Holding SA, Annual General Meeting, Jun 27, 2024

Relief Therapeutics Announces Executive Changes

New major risk - Share price stability

Full year 2023 earnings released: CHF8.35 loss per share (vs CHF4.81 loss in FY 2022)

New minor risk - Financial data availability

Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor

Less than half of directors are independent

Relief Therapeutics Holding Sa Announces CEO Changes

First half 2023 earnings released: CHF5.10 loss per share (vs CHF2.55 loss in 1H 2022)

New major risk - Financial position

Relief Therapeutics Holding AG announced that it expects to receive CHF 5 million in funding

Relief Therapeutics Holding AG, Annual General Meeting, Jun 20, 2023

Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?

Relief Therapeutics Announces Enrollment of First Three Patients in Proof-Of-Concept Clinical Trial of Rlf-Td011 for the Treatment of Epidermolysis Bullosa

RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ for Patients with Urea Cycle Disorders

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

Relief Therapeutics Holding AG Appoints Jeremy Meinen as Chief Financial Officer

No independent directors

Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

RELIEF THERAPEUTICS Holding SA Promotes Paolo Galfetti to Chief Operating Officer

Relief Therapeutics Holding SA Announces U.S. Launch of PKU GOLIKE

Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?

Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa At Ann & Robert H. Lurie Children's Hospital of Chicago

Relief Therapeutics Holding AG has filed an IPO.

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation

Relief Therapeutics Holding SA Appoints David McCullough as Head of U.S. Market Access, Effective August 22, 2022

Relief Therapeutics Holding Ag Announces U.S. Food and Drug Administration Accepts for Review Acer’s Resubmitted New Drug Application

Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

Relief Therapeutics Expands U.S. Commercial Team

Relief Therapeutics Holding AG, Annual General Meeting, May 31, 2022

Price target decreased to CHF0.41

No independent directors

Relief Therapeutics Holding AG Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Relief Therapeutics Holding SA Files Trademark Application for RLF-100 with the U.S. Patent and Trademark Office

Relief Therapeutics Holding AG Approves Election of Michelle Lock as New Member of the Board of Directors

NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics

Relief Therapeutics Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-Induced Pneumonitis

Relief Therapeutics Holding SA Announces New Safety Update on Aviptadil

Chief Commercial Officer Christiaan L. J. Stijnen has left the company

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Relief Therapeutics Holding AG (SWX:RLF) completed the acquisition of APR Applied Pharma Research s.a.

Relief Provides Update on Progress and Plans with Acer-001 for the Treatment of Urea Cycle Disorders

Relief Therapeutics Holding AG (SWX:RLF) signed binding term sheet to acquire APR Applied Pharma Research s.a. for CHF.

New 90-day low: CHF0.27

Relief Therapeutics Successfully Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure Among Critically Iii Patients with Covid-19

NeuroRx and Relief Therapeutics Holding AG Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19